Hologic launches on-demand molecular testing in Europe

By LabPulse.com staff writers

October 6, 2021 -- Hologic has launched its Novodiag on-demand molecular test for infectious diseases and antibiotic resistance in Europe.

Novodiag features real-time polymerase chain reaction and microarray capabilities that allow for multiple pathogens to be identified from a single sample, Hologic said. Its CE-marked IVD test menu includes assays for gastrointestinal infection, antibiotic resistance, and SARS-CoV-2.

The Novodiag European launch comes after Hologic's June purchase of Mobidiag; Novodiag is part of that company's offerings, according to Hologic. Novodiag complements Hologic's Panther laboratory testing system, the company said.

Hologic posts strong Q3 revenues
Hologic posted strong revenues for its fiscal third quarter. The company attributed the solid financial results in part to recovery from the COVID-19...
Hologic gets CE Mark for COVID-19 test
Hologic announced it has received the CE Mark for the use of saliva samples with its Aptima SARS-CoV-2 assay in Europe. The assay also has the CE Mark...
Hologic receives CE Mark for CMV detection assay
Hologic has received the CE Mark for its molecular assay to quantify human cytomegalovirus (CMV). The Aptima CMV Quant assay is the company's first test...
Ink dries on Hologic's deal to buy Mobidiag
Hologic announced the completion of its $808 million acquisition of biotechnology company Mobidiag. The Finnish-French company develops near-patient,...
Hologic's growth continues in Q2
Hologic has continued to post significant increases in revenue, with revenues doubling in the company's second quarter. The growth was driven primarily...

Copyright © 2021 LabPulse.com

Last Updated ls 10/6/2021 1:05:48 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current